EQUIP - Evaluation of Quality of Imaging on a Next-generation Total Body Pet Scan in Comparison to Conventional PET

New PET Scanner Trial: Better Imaging with Less Radiation?

NCT: NCT07263815 · Status: ACTIVE NOT RECRUITING · Phase: N/A · Sponsor: Peter MacCallum Cancer Centre, Australia · Started: 2025-11-24 · Est. Completion: 2026-12-24

Plain English Summary

EQUIP - Evaluation of Quality of Imaging on a Next-generation Total Body Pet Scan in Comparison to Conventional PET is a Not Applicable clinical trial sponsored by Peter MacCallum Cancer Centre, Australia studying Cancer. This trial tests a new, advanced whole-body PET scanner to see if it provides clearer images than current scanners. It's for adult cancer patients who are already scheduled for a PET scan using specific radioactive tracers. Participation involves having a PET scan on both the new and the current scanner, with no extra radioactive tracer given. Alternatives include standard PET scans with existing technology. The trial aims to enroll 25 participants.

Official Summary

The GE Healthcare Omni Total Body (TB) 128cms (Omni TB) is a long-axial field-of-view (LAFOV) PET/CT scanner and will be installed in a pre-market phase at the Peter MacCallum Cancer Centre. The main features and functionality of this new scanner include high sensitivity, high resolution digital detectors based on silicon photomultipliers. The ultra-high sensitivity and extended field of view are designed to support the ability to reduce administrated dose and/or shorten acquisition time without compromising the image quality of the PET imaging. To verify the appearance of images acquired on the Omni TB with images acquired on our conventional PET/CT equipment, a study imaging a cohort of patients on both devices is proposed. The study involves no additional radiopharmaceutical administration. Additionally, in keeping with ALARA (as low as reasonably achievable) radiation dose practices, it will be possible to model acquisition settings (duration, administered activity and reconstruction parameters) using the system raw data and a suite of research tools to optimise acquisition parameters.

Who Can Participate

Here is what you need to know about eligibility for this trial. Adults aged 18 or older can join. You must be referred for a PET scan using specific tracers (F-18 FDG, F-18 DCFPyL, Ga-68 PSMA, Ga-68 DOTATATE, or I-124). You cannot join if you are pregnant or breastfeeding. This trial is studying Cancer, so participants generally need a confirmed diagnosis.

What They're Measuring

The primary outcome measures how good the images from the new scanner are, meaning it will help determine if this new technology can provide clear and useful pictures for doctors. The specific primary outcome measures are: To assess the diagnostic quality of images acquired on the OMNI 128 Total Body PET (1 Day). These endpoints are how researchers determine whether the treatment is effective and will form the basis of any future regulatory submissions.

About This Phase

This study does not have a traditional clinical phase designation. It may be an observational study that follows patients without intervening in their care, an expanded access or compassionate use program, or other non-interventional research. These studies contribute valuable data about disease progression, treatment patterns, and patient outcomes.

Why This Trial Matters

This trial matters because it evaluates a new PET scanner that could improve cancer detection and treatment monitoring by providing higher quality images with potentially lower radiation doses or shor This research targets Cancer, where improved treatment options are needed.

Investor Insight

This trial signals a significant advancement in diagnostic imaging technology, potentially impacting the market for PET scanners and offering a competitive edge for companies developing next-generatio

Is This Trial Right for Me?

Ask your doctor if this trial is a good fit for you and what the scan involves. You will have two PET scans: one on the new scanner and one on the current scanner, using the same radioactive tracer you would normally receive. There is no extra radioactive tracer needed for this study. The trial is being conducted at 1 site. Always discuss clinical trial participation with your healthcare provider before making any decisions. This information is for educational purposes only and is not medical advice.

AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.

Study Design

Interventions

Primary Outcomes

Secondary Outcomes

Full Eligibility Criteria

Inclusion Criteria:

1. Adult, who is at least 18 years of age
2. Referred for a clinically indicated PET/CT scan with radiotracers F-18 FDG, F-18 DCFPyL, Ga-68 PSMA, Ga-68 DOTATATE or I-124
3. Able and willing to provide informed consent for participation in this study

Exclusion Criteria:

1\) Known to be pregnant or breastfeeding

Trial Locations

Frequently Asked Questions

What is clinical trial NCT07263815?

NCT07263815 is a Not Applicable INTERVENTIONAL study titled "EQUIP - Evaluation of Quality of Imaging on a Next-generation Total Body Pet Scan in Comparison to Conventional PET." It is currently active, not recruiting and is sponsored by Peter MacCallum Cancer Centre, Australia. The trial targets enrollment of 25 participants.

What conditions does NCT07263815 study?

This trial investigates treatments for Cancer. The primary condition under study is Cancer.

What treatments are being tested in NCT07263815?

The interventions being studied include: PET (DEVICE). This device images the whole body simultaneously with greater sensitivity allowing imaging to occur faster and with less radiation dose compared to conventional PET systems

What does Not Applicable mean for NCT07263815?

This study does not have a defined clinical phase. It may be an observational study, expanded access program, or other non-interventional research.

What is the current status of NCT07263815?

This trial is currently "Active, Not Recruiting." It started on 2025-11-24. The estimated completion date is 2026-12-24.

Who is sponsoring NCT07263815?

NCT07263815 is sponsored by Peter MacCallum Cancer Centre, Australia. The sponsor is responsible for funding, designing, and overseeing the clinical trial.

How many people can participate in NCT07263815?

The trial aims to enroll 25 participants. The trial status is active, not recruiting.

How is NCT07263815 designed?

This is a interventional study, uses na allocation, follows a single_group design, employs none masking.

What are the primary outcomes being measured in NCT07263815?

The primary outcome measures are: To assess the diagnostic quality of images acquired on the OMNI 128 Total Body PET (1 Day). These are the main endpoints researchers use to determine whether the treatment is effective.

Where is NCT07263815 being conducted?

This trial is being conducted at 1 site, including Melbourne, Victoria (Australia).

Where can I find official information about NCT07263815?

The official record for NCT07263815 is available on ClinicalTrials.gov at https://clinicaltrials.gov/study/NCT07263815. This government database provides the most up-to-date and detailed information about the trial.

What is NCT07263815 testing in simple terms?

This trial tests a new, advanced whole-body PET scanner to see if it provides clearer images than current scanners. It's for adult cancer patients who are already scheduled for a PET scan using specific radioactive tracers.

Why is this trial significant?

This trial matters because it evaluates a new PET scanner that could improve cancer detection and treatment monitoring by providing higher quality images with potentially lower radiation doses or shor

What are the potential risks of participating in NCT07263815?

The main risk is the standard risk associated with PET scans, including exposure to a small amount of radiation from the tracer. Potential side effects from the radioactive tracer are generally mild and temporary, such as nausea or a headache. As with any clinical trial, participants are closely monitored and can withdraw at any time.

Should I consider participating in NCT07263815?

Ask your doctor if this trial is a good fit for you and what the scan involves. You will have two PET scans: one on the new scanner and one on the current scanner, using the same radioactive tracer you would normally receive. There is no extra radioactive tracer needed for this study. Always discuss clinical trial participation with your healthcare provider to determine if it is appropriate for your specific situation.

What does NCT07263815 signal from an investment perspective?

This trial signals a significant advancement in diagnostic imaging technology, potentially impacting the market for PET scanners and offering a competitive edge for companies developing next-generatio This is a Not Applicable trial, which is in early development stages.

What happens if the treatment in this trial doesn't work?

Participation involves having a PET scan on both the new and the current scanner, with no extra radioactive tracer given. Participants in clinical trials always have the right to withdraw and pursue alternative treatments. The study team will help transition patients to other available options.

Related Conditions

More Cancer Trials

View all Cancer clinical trials

This analysis is AI-generated and does not constitute medical advice. Always consult your healthcare provider before making decisions about clinical trial participation.